Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides

Abstract

Purpose: Fibroblast activation protein-α (FAP)-targeting radioligands have recently demonstrated high diagnostic potential. However, their therapeutic value is impaired by the short tumor residence time. Several strategies have been tested to overcome this limitation, but a head-to-head comparison has never been done. With the aim to identify strengths and limitations of the suggested strategies, we compared the monomer FAPI-46 versus (a) its dimer (FAPI-46-F1D), (b) two albumin binders conjugates (FAPI-46-Ibu (ibuprofen) and FAPI-46-EB (Evans Blue)), and (c) cyclic peptide FAP-2286.

Methods: ¹⁷⁷Lu-labeled ligands were evaluated in vitro in cell lines with low (HT-1080.hFAP) and high (HEK-293.hFAP) humanFAP expression. SPECT/CT imaging and biodistribution studies were conducted in HT-1080.hFAP and HEK-293.hFAP xenografts. The areas under the curve (AUC) of the tumor uptake and tumor-to-critical-organs ratios and the absorbed doses were estimated.

Results: Radioligands showed IC₅₀ in the picomolar range. Striking differences were observed in vivo regarding tumor uptake, residence, specificity, and total body distribution. All [¹⁷⁷Lu]Lu-FAPI-46-based radioligands showed similar uptake between the two tumor models. [¹⁷⁷Lu]Lu-FAP-2286 showed higher uptake in HEK-293.hFAP and the least background. The AUC of the tumor uptake and absorbed dose was higher for [¹⁷⁷Lu]Lu-FAPI-46-F1D and the two albumin binder conjugates, [¹⁷⁷Lu]Lu-FAPI-46-Ibu and [¹⁷⁷Lu]Lu-FAPI-46-EB, in HT1080.hFAP xenografts and for [¹⁷⁷Lu]Lu-FAPI-46-EB and [¹⁷⁷Lu]Lu-FAP-2286 in HEK293.hFAP xenografts. The tumor-to-critical-organs AUC values and the absorbed doses were in favor of [¹⁷⁷Lu]Lu-FAP-2286, but tumor-to-kidneys.

Conclusion: The study indicated dimerization and cyclic peptide structures as promising strategies for prolonging tumor residence time, sparing healthy tissues. Albumin binding strategy outcome depended on the albumin binding moiety. The peptide showed advantages in terms of tumor-to-background ratios, besides tumor-to-kidneys, but its tumor uptake was FAP expression-dependent.

Keywords: Albumin binder; Dimer; FAP-2286; FAPI; Fibroblast activation protein-α (FAP); Radioligand therapy.